COMPOUND PROFILE / PROTEINS & BIOLOGICS
IGF-1 LR3.
Research draftIGF-1 LR3 is a modified IGF-1 analogue used in research and enhancement markets.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
IGF-1 LR3 is a modified IGF-1 analogue used in research and enhancement markets.
Mechanism
Its altered sequence affects interactions with IGF-binding proteins; it is not native IGF-1.
Human research
A reliable direct clinical evidence base for current LR3 products was not established.
Preclinical & other research
Laboratory IGF signalling does not establish human efficacy or safety for this analogue.
Safety & unknowns
Altered exposure, hypoglycaemia potential and growth-related effects remain insufficiently assessed clinically.
Regulatory status
No therapeutic approval is established here; mecasermin's approval is not applicable.
Reported use & evidence
The supplied IGF-1 LR3 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.